Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects With Presbyopia

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects With Presbyopia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pilocarpine (Primary)
  • Indications Presbyopia
  • Focus Registrational; Therapeutic Use
  • Acronyms VIRGO
  • Sponsors Allergan

    • Most Recent Events

    • 18 Aug 2023 Results assessing the safety, efficacy, and pharmacokinetics of pilocarpine hydrochloride 1.25% (Pilo hereafter) compared with vehicle when administered bilaterally, twice daily (6 hours apart) for 14 days in participants with presbyopia published in the American Journal of Ophthalmology
    • 05 Apr 2022 According to an Allergan media release, Christopher Lievens, O.D is the investigator for this trial.
    • 05 Apr 2022 According to an Allergan media release, the company to submit supplemental New Drug Application submission for twice-daily administration of VUITY™ (pilocarpine HCI ophthalmic solution) to the U.S. Food and Drug Administration (FDA) in the second quarter of 2022, based on data from this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top